Skip to main content
TipRanks
Go Ultimate75% OFF

Neola Medical AB (NEOLA) AI Stock Analysis

0 Followers
SE:NEOLA

Neola Medical AB

(Nasdaq OMX AB:NEOLA)

Select Model
Rating:40Underperform
Price Target:SEK 0.45â–¼(-3.83% Downside)
Action:downgraded
Date:09/09/26

The low score is primarily driven by weak financial performance due to lack of revenue and ongoing losses, compounded by unfavorable valuation. Technical indicators show mixed signals without strong momentum.

Positive Factors
Debt-Free Balance SheetZero reported debt limits interest obligations and refinancing exposure, while substantial equity provides a financial buffer for continued product development. This gives Neola greater flexibility than a similarly loss-making company with leverage, although ongoing losses could reduce that buffer over time.
Negative Factors
No Meaningful Revenue YetThe absence of meaningful revenue indicates that Neola has not yet demonstrated commercial adoption or a functioning revenue engine. This leaves the business dependent on future product commercialization and external funding, while making it difficult to assess sustainable demand, pricing power, or operating leverage.

Neola Medical AB (NEOLA) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:NEOLA-65.47%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 51.92M
Dividend Yield
―
Average Volume (3M)
108.59K
Price to Earnings (P/E)
-2.9
Beta (1Y)
-0.40
Revenue Growth
―
EPS Growth
-13.49%
Country
Sweden
Employees
9
Sector
General
Sector Strength
55
Industry
Medical - Devices

Neola Medical AB Business Overview & Revenue Model

Company Description

Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care. Th...

How the Company Makes Money

Neola Medical AB’s revenue model is primarily tied to commercializing its medical device(s) for neonatal monitoring, which would typically generate income through sales of devices to hospitals/clinics and potentially recurring revenue from associated...

Neola Medical AB Financial Statement Overview

Summary

Neola Medical shows no revenue and persistent losses in income statement and cash flows, though the debt-free balance sheet with increasing equity provides some stability.

Income Statement

10Very Negative

Balance Sheet

65Positive

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue00000625.00K
Gross Profit3.50M-1.39M-1.53M-1.43M-571.00K-7.36M
EBITDA-7.34M-9.75M-8.54M-7.42M-9.32M-6.64M
Net Income-8.38M-11.02M-10.06M-9.01M-10.35M-6.65M
Balance Sheet
Total Assets78.80M78.80M73.61M86.02M75.33M43.83M
Cash, Cash Equivalents and Short-Term Investments16.12M16.12M19.55M21.58M40.09M22.94M
Total Debt000000
Total Liabilities3.00M3.00M4.65M6.99M7.84M3.19M
Stockholders Equity75.80M75.80M68.96M79.03M67.48M40.63M
Cash Flow
Free Cash Flow-9.50M-21.25M-10.84M-18.85M-20.05M-17.45M
Operating Cash Flow-8.90M-11.95M-10.84M-6.54M-8.50M-6.93M
Investing Cash Flow-7.57M-9.34M-11.18M-12.30M-11.56M-10.52M
Financing Cash Flow-68.00K17.86M20.00M336.00K37.20M23.74M

Neola Medical AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.47

Price Trends

50DMA0.50Negative
100DMA0.57Negative
200DMA0.73Negative

Market Momentum

MACD-0.01Positive
RSI42.18Neutral
STOCH15.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NEOLA, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.50, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.18 is Neutral, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NEOLA.

Neola Medical AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:NEOLA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:SEZISE:SEZI55NeutralSEK 528.24M-5.42-35.44%―18.56%28.11%
SE:BRAINSE:BRAIN54NeutralSEK 473.85M-12.99-19.29%―0.04%34.45%
SE:BACTI.BSE:BACTI.B53NeutralSEK 544.93M86.391.93%―-0.51%―
SE:SEDANASE:SEDANA49NeutralSEK 921.85M-26.71-3.88%―0.42%15.03%
SE:ACARIXSE:ACARIX45NeutralSEK 201.21M-5.10-96.06%―40.61%32.63%
SE:NEOLASE:NEOLA40UnderperformSEK 51.92M-2.88―――-13.49%

* General Sector Average

Performance Comparison

-50%0%50%100%SE:NEOLASE:SEZISE:BACTI.BSE:ACARIXSE:BRAINSE:SEDANADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:NEOLA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:NEOLANeola Medical AB0.47-0.91-65.97%
SE:SEZISenzime AB3.36-1.59-32.12%
SE:BACTI.BBactiguard Holding AB15.55-3.20-17.07%
SE:ACARIXAcarix AB0.16-0.12-41.73%
SE:BRAINBrainCool AB1.200.61105.13%
SE:SEDANASedana Medical AB9.28-0.33-3.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 09, 2026